Vanda Pharmaceuticals Inc.
GENETIC MARKERS FOR ENHANCING EFFICACY OF ANTIPSYCHOTIC TREATMENT WITH ILOPERIDONE

Last updated:

Abstract:

The present invention relates to the selection of patients with enhanced antipsychotic treatment efficacy with iloperidone based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to treatment of such patients based upon the identification of their genetic information.

Status:
Application
Type:

Utility

Filling date:

29 Nov 2021

Issue date:

17 Mar 2022